Bloodstream infections in cancer patients with febrile neutropenia

被引:74
|
作者
Feld, Ronald [1 ]
机构
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Med,Div Hematol & Med Oncol, Toronto, ON M5G 2M9, Canada
关键词
Bacteraemia; Febrile neutropenia; Predictive laboratory markers;
D O I
10.1016/j.ijantimicag.2008.06.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bloodstream infections (bacteraemia) account for approximately 25-30% of febrile episodes in patients with febrile neutropenia (FN). In developed countries, Gram-positive pathogens predominate. Mortality is higher in Gram-negative bacteraemia. A recent study involving 2142 patients with FN was reviewed, including 168 patients with Gram-negative bacteraemia (mortality 18%), 283 patients with Gram-positive bacteraemia (mortality 5%) and 48 patients with polymicrobial bacteraemia (mortality 13%). Among patients who received prophylactic antibiotics, Gram-positive bacteraemia was far more common than Gram-negative bacteraemia (75% vs. 25%), compared with approximately 50% of each in patients without prophylactic antibiotics. Patients with a Multinational Association for Supportive Care in Cancer (MASCC) score < 15 had a 36% mortality compared with 3% if the MASCC score was > 21. The MASCC score may help risk strati. cation of patients with FN and bacteraemia, although these data require confirmation. In two series of patients from developing countries (Lebanon and Malaysia), Gram-negative bacteraemia was more common and mortality was higher. In developing countries, Gram-negative bacteraemia may be more frequent due to less use of prophylactic antibiotics and central lines. Laboratory markers may have predictive and prognostic value for bacteraemia in patients at the onset of FN, including mannose-binding lectin, interleukin (IL)-6, IL-8 and procalcitonin, but further studies are required before they can be recommended. New therapies are required to lower the mortality in patients with FN with a high risk for bacteraemia. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:S30 / S33
页数:4
相关论文
共 50 条
  • [41] PREVALENCE OF PATHOGENS IN PEDIATRIC CANCER PATIENTS WITH FEBRILE NEUTROPENIA
    Vathana, Nassawee
    Thitipolpun, Siriporn
    Buaboonnam, Jassada
    Phuakpet, Kamon
    Sanpakit, Kleebsabai
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2017, 48 : 151 - 160
  • [42] Hospitalization with febrile neutropenia in colorectal cancer patients.
    Culakova, E
    Khorana, A
    Kuderer, NM
    Crawford, J
    Dale, DC
    Lyman, GH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 295S - 295S
  • [43] Time to antibiotics and outcomes in cancer patients with febrile neutropenia
    Thomas Perron
    Mohamed Emara
    Shahid Ahmed
    BMC Health Services Research, 14
  • [44] Variation in antimicrobial utilization for febrile neutropenia in cancer patients
    Harbarth, S
    Viot, M
    Beeler, I
    Klastersky, J
    Szucs, T
    INFECTION, 2000, 28 (06) : 375 - 378
  • [45] Management of Infection and Febrile Neutropenia in Patients with Solid Cancer
    Maria Aguado, Jose
    Jesus Cruz, Juan
    Antonio Virizuela, Juan
    Aguilar, Manuela
    Carmona, Alberto
    Cassinello, Javier
    Gudiol, Carlota
    Jimenez Fonseca, Paula
    Lizasoain, Manuel
    Marco, Francesc
    Ruiz, Isabel
    Ruiz, Maribel
    Salavert, Miguel
    Vicente, David
    Carratala, Jordi
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2017, 35 (07): : 451 - 460
  • [46] Cefepime monotherapy for febrile neutropenia in patients with lung cancer
    Saito, Hiroshi
    Takahashi, Kosuke
    Okuno, Motoyasu
    Saka, Hideo
    Imaizumi, Kazuyoshi
    Hasegawa, Yoshinori
    Tanikawa, Yoshimasa
    Yamamoto, Masashi
    Taniguchi, Hiroyuki
    Shindoh, Joe
    Suzuki, Ryujiro
    Shimokata, Kaoru
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (5-6) : 365 - 369
  • [47] Identification of cancer patients at high risk of febrile neutropenia
    Scott, S
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 : S16 - S19
  • [48] Risk of mortality in patients with cancer experiencing febrile neutropenia
    Lyman, G. H.
    Michels, S. L.
    Tomic, K. E.
    Yu, J.
    Reynolds, M. W.
    Barron, R. L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 176 - 177
  • [49] Management of infection and febrile neutropenia in patients with solid cancer
    Virizuela, J. A.
    Carratala, J.
    Aguado, J. M.
    Vicente, D.
    Salavert, M.
    Ruiz, M.
    Ruiz, I.
    Marco, F.
    Lizasoain, M.
    Jimenez-Fonseca, P.
    Gudiol, C.
    Cassinello, J.
    Carmona-Bayonas, A.
    Aguilar, M.
    Cruz, J. J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06): : 557 - 570
  • [50] Variation in Antimicrobial Utilization for Febrile Neutropenia in Cancer Patients
    S. Harbarth
    M. Viot
    I. Beeler
    J. Klastersky
    T. Szucs
    Infection, 2000, 28 : 375 - 378